GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis

ClinicalTrials.gov ID: NCT00737672

Public ClinicalTrials.gov record NCT00737672. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

GORE VIABAHN® Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise Arteriovenous Grafts at the Venous Anastomosis in Hemodialysis Patients

Study identification

NCT ID: NCT00737672
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: W.L.Gore & Associates; Industry
Enrollment: 293 participants

Conditions and interventions

Conditions

Interventions

GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface Device
Percutaneous Transluminal Angioplasty Procedure

Device · Procedure

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2008
Primary completion: Apr 30, 2011
Completion: May 31, 2013
Last update posted: Oct 20, 2014

2008 – 2013

United States locations

U.S. sites: 31
U.S. states: 18
U.S. cities: 29

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35249	—
Not listed	Fresno	California	93710	—
Not listed	Inglewood	California	90301	—
Not listed	Oceanside	California	92056	—
Not listed	Riverside	California	92501	—
Not listed	San Diego	California	92115	—
Not listed	San Diego	California	92120	—
Not listed	San Francisco	California	94143	—
Not listed	New Haven	Connecticut	06520	—
Not listed	Jacksonville	Florida	32209	—
Not listed	Albany	Georgia	31707-1908	—
Not listed	Chicago	Illinois	60612-3833	—
Not listed	Des Moines	Iowa	50309	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Baltimore	Maryland	21239	—
Not listed	New Brighton	Minnesota	55112	—
Not listed	Saint Paul	Minnesota	55101	—
Not listed	Cincinnati	Ohio	45212	—
Not listed	Cincinnati	Ohio	45267-0585	—
Not listed	Dayton	Ohio	45406	—
Not listed	Portland	Oregon	97210	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Charleston	South Carolina	29421	—
Not listed	Greenville	South Carolina	29615	—
Not listed	Beaumont	Texas	77701	—
Not listed	Houston	Texas	77030	—
Not listed	Norfolk	Virginia	23507	—
Not listed	Winchester	Virginia	22601	—
Not listed	Bellevue	Washington	98004	—
Not listed	Spokane	Washington	99204	—
Not listed	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00737672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 20, 2014 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00737672 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →